Livemedia Home
facebook_icon twitter_icon youtube_icon instagram rss_icon

 Login / Register to Livemedia


A+ | A-
GR | GLOBAL | UK

03/05/2019 Congresses | Transcatheter Heart Valves Greece 2019

Congresses | Transcatheter Heart Valves Greece 2019  
 

Share

18.774 total
707 live
8.592 video
5.283 photo
Views:
 
Sort by Date | Views

Το 8o Συνέδριο Διακαθετηριακής Θεραπείας Καρδιακών Βαλβιδοπαθειών θα μεταδοθεί ζωντανά στο Livemedia
3 - 4 Μαίου 2019. Το Συνέδριο διοργανώνεται από το Διαγνωστικό Θεραπευτήριο Κέντρο Αθηνών Υγεία και θα πραγματοποιηθεί στο Μέγαρο Μουσικής Αθηνών.

Για περισσότερες πληροφορίες πατήστε εδώ.

Webtv: THVgreece WebTV
03/05 Banquet Hall, MAICC
09:00 - 11:00
TAVI Session I – TAVR Technology in a Rapidly-Evolving Era 

Evaluated
Evaluation
09:00 - 09:15
Latest TAVR Randomized Trials

Evaluated
Evaluation

Speaker: G. Pattakos(   )

09:15 - 09:30
High-Quality TAVR: Does a minimum volume requirement still make sense?

Evaluated
Evaluation

Speaker: M. Vavuranakis(   )

09:30 - 09:45
The selection of SAVR devices in the TAVR era

Evaluated
Evaluation

Speaker: S. Prapas(   )

09:45 - 10:00
Rapid Deployment Surgical Valves with Minimally invasive techniques. Can they compete with TAVR?

Evaluated
Evaluation

Speaker: P. Dedeilias

10:00 - 10:15
TAVR for low-risk patients with a self-expanding valve

Evaluated
Evaluation

Speaker: N. Kleiman

10:15 - 10:30
Live-in-a-box TAVR

Evaluated
Evaluation
10:45 - 11:00
Discussion

Chairmen: I. Goudevenos, J. Kanakakis, D. Sionis, P. Vardas

Commentators: S. Karagiannis, G. Makos, A. Tzikas

11:00 - 11:30
WELCOME NOTES 

Evaluated
Evaluation

Chairmen: S. Pattakos, S. Konstantinidis, I. Goudevenos, D. Tousoulis, P. Vardas, A. Kartapanis

11:30 - 13:30
TAVR Session II – TAVR on the Uprise. How do we deal with complex situations? 

Evaluated
Evaluation
12:00 - 12:10
CT Imaging of Bicuspid Aortic Valve Disease. Anatomic patterns favorable and unfavorable for TAVR and factors influencing device selection

Evaluated
Evaluation

Speaker: A. Chalapas(   )

12:10 - 12:20
TAVR will be the treatment of choice for bicuspid aortic valve disease in the future!

Evaluated
Evaluation

Speaker: N. Van Mieghem(   )

12:20 - 12:30
Most Bicuspid aortic valves (especially In younger low-risk patients) will remain in the surgical domain!

Evaluated
Evaluation

Speaker: D. Angouras(   )

12:30 - 12:40
Strokes After TAVR and SAVR: Incidence in the "Modern Era" and Key Messages

Evaluated
Evaluation

Speaker: S. Kodali(   )

12:40 - 12:50
What’s Holding Back Cerebral Embolic Protection in TAVR? Data or Money?

Evaluated
Evaluation

Speaker: R. Mehran(   )

12:50 - 13:00
TAVR in the patient with significant native or bioprosthetic mitral and/or tricuspid valve disease

Evaluated
Evaluation

Speaker: M. Οto

13:00 - 13:15
Live-in-a-box TAVR

Evaluated
Evaluation
13:15 - 13:30
Discussion

Chairmen: M. Argiriou, S. Foussas, E. Pissimisis, C. Tsioufis

Commentators: K. Aznaouridis, V. Androutsopoulou, S. Makrigiannis

13:30 - 14:00
BREAK 

14:00 - 15:45
TAVI Session III – TAVR dilemmas and complications 

Evaluated
Evaluation
14:00 - 14:15
Incidence, predictors and consequences of new LBBB and new PPM after TAVR

Evaluated
Evaluation

Speaker: L. Papavasileiou(   )

14:15 - 14:30
Is paravalvular regurgitation after TAVR still an important consideration in 2019?

Evaluated
Evaluation

Speaker: N. Kleiman(   )

14:30 - 14:45
A Selective versus Routine Minimalist Strategy. Is every patient eligible?

Evaluated
Evaluation

Speaker: S. Kapadia(   )

14:45 - 15:00
Management of Coronary Disease in AS Patients: Important Treatment Considerations (When to consider CABG, timing of PCI and TAVR, and completeness of revascularization)

Evaluated
Evaluation

Speaker: M. Οto

15:00 - 15:15
To crack or not to crack? The role for fracturing bioprosthetic valves during ViV procedures

Evaluated
Evaluation

Speaker: M. Kasel

15:15 - 15:30
Live-in-a-box TAVR

Evaluated
Evaluation
15:30 - 15:45
Discussion

Evaluated
Evaluation

Chairmen: D. Iliopoulos, G. Hahalis, V. Pyrgakis, S. Tzeis

Commentators: I. Chlorogiannis, K. Dimitriadis, A. Zacharoulis

15:45 - 16:00
Break 

Evaluated
Evaluation
16:00 - 17:30
JOINT SESSON I 

Aortic and Mitral Club

Evaluated
Evaluation
16:00 - 16:15
In hospital mortality after TAVR. Common and uncommon causes

Evaluated
Evaluation

Speaker: S. Kodali(   )

16:15 - 16:28
Impact of valvular heart disease on the global burden of heart failure: Can transcatheter therapies make a difference?

Evaluated
Evaluation

Speaker: A. Katsaros(   )

16:28 - 16:40
Patient-prosthesis mismatch after transcatheter aortic valve replacement: prevalence and long-term impact

Evaluated
Evaluation

Speaker: A. Patrianakos(   )

16:40 - 16:52
Moderate aortic stenosis with reduced ejection fraction: Can imaging guide therapy?

Evaluated
Evaluation

Speaker: E. Anagnostou

16:52 - 17:04
Minimally invasive surgery for the Mitral Valve. Hard to Beat!

Evaluated
Evaluation

Speaker: G. Pattakos(   )

17:04 - 17:16
Can Transcatheter Edge-to-Edge, direct or indirect Mitral Rings and Chords Match or Exceed Open Surgical Procedures?

Evaluated
Evaluation

Speaker: S. Kodali(   )

Chairmen: S. Adamopoulos, C. Chrysohoou, G. Filippatos

Commentators: G. Giamouzis, G. Karatasakis

17:30 - 18:30
JOINT KEY LECTURES 

Evaluated
Evaluation
17:30 - 17:50
TAVR for All? New insights from the low-risk trials

Evaluated
Evaluation

Speaker: S. Kapadia(   )

17:50 - 18:10
Defining Secondary Mitral Regurgitation: Get it Right!

Evaluated
Evaluation

Speaker: J. Kisslo

18:10 - 18:30
Mitraclip for Functional Mitral Regurgitation

Evaluated
Evaluation

Speaker: S. Kar(   )

Chairmen: P. Nihoyannopoulos, P. Vardas

18:30 - 20:00
JOINT SESSION II  

Mitral and Tricuspid Club

Evaluated
Evaluation
18:30 - 18:45
Exercise-stress echocardiography and effort intolerance in asymptomatic/symptomatic degenerative mitral regurgitation

Evaluated
Evaluation

Speaker: D. Klettas

18:45 - 19:00
Mitraclip vs. PASCAL. Similarities and differences

Evaluated
Evaluation

Speaker: K. Spargias

19:00 - 19:15
Lessons from the MITRA-FR and COAPT studies; How should we quantify MR?

Evaluated
Evaluation

Speaker: K. Papadopoulos

19:15 - 19:30
Percutaneous mitral repair after failed open surgery

Evaluated
Evaluation

Speaker: S. Kar(   )

19:30 - 19:45
Who are the best candidates for experimental TMVR in 2019?

Evaluated
Evaluation

Speaker: N. Kleiman(   )

19:45 - 20:00
Lessons from an International Registry on Transcatheter Tricuspid Thearapies

Evaluated
Evaluation

Speaker: F. Maisano

Chairmen: G. Athanassopoulos, G. Giamouzis, A. Trikas

04/05 Banquet Hall, MAICC
08:45 - 11:00
Mitral Session I – Complexities of Mitral Interventions 

Evaluated
Evaluation
08:45 - 09:00
Echocardiographic evaluation of the mitral valve. A guide to decision-making for transcatheter or surgical Repair / Replacement

Evaluated
Evaluation

Speaker: M. Chrissoheris(   )

09:00 - 09:15
Advanced Applications of CT Imaging for Transcatheter Mitral and Tricuspid Procedures

Evaluated
Evaluation

Speaker: C. Mourmouris

09:15 - 09:30
Mitral Valve-in-valve and valve-in-ring procedures. A long-needed necessity!

Evaluated
Evaluation

Speaker: A. Pitsis

09:30 - 09:45
Results of valve-in-MAC (mitral annular calcification) procedures. Assess and plan carefully!

Evaluated
Evaluation

Speaker: J. Velianou(   )

09:45 - 10:00
Currently enrolling TMVR and TTVR FIM and CE Mark trials

Evaluated
Evaluation

Speaker: S. Kar(   )

10:00 - 10:15
You can’t beat safety and simplicity: Edge to edge therapies will be the dominant strategy for mitral repair

Evaluated
Evaluation

Speaker: F. Maisano(   )

10:30 - 10:45
Live in a box Mitraclip

Evaluated
Evaluation
10:45 - 11:00
Discussion

Chairmen: L. Poulimenos, G. Stavridis, D. Tsiapras, M. Vavuranakis

Commentators: N. Baikoussis, K. Bellos, E. Petropoulou

11:00 - 13:00
TAVI Session IV – Avoiding Pitfalls 

Evaluated
Evaluation
11:00 - 11:15
A growing conundrum: Coronary access after TAVR. Difficulties, tips and tricks

Evaluated
Evaluation

Speaker: V. Voudris(   )

11:15 - 11:30
Mechanisms of coronary obstruction during and after TAVR: prediction, prevention, and treatment

Evaluated
Evaluation

Speaker: N. Van Mieghem(   )

11:30 - 11:45
Hybrid beating heart bypass grafting and TAVR. An excellent alternative?

Evaluated
Evaluation

Speaker: N. Bouboulis(   )

11:45 - 12:00
Guidelines and classification of bioprothetic TAVR and SAVR dysfunction and failure. Latest data on incidence, clinical impact and valve durability

Evaluated
Evaluation

Speaker: A. Manginas(   )

12:00 - 12:15
TAVR plus/minus AFib and/or CAD. Pharmacotherapy considerations, clinical trials and practical clinical recommendations

Evaluated
Evaluation

Speaker: R. Mehran(   )

12:15 - 12:30
The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Evaluated
Evaluation

Speaker: G. Dangas(   )

12:30 - 12:45
Live-in-a-box TAVR

Evaluated
Evaluation
12:45 - 13:00
Discussion

Chairmen: D. Alexopoulos, I. Ikonomidis, A. Manginas, A. Pipilis

Commentators: N. Kadoglou, A. Roubelakis, G. Tsigas

13:00 - 13:30
BREAK 

13:30 - 15:00
TAVR Session V – Dealing with a “gray area”. Crucial questions and answers 

Evaluated
Evaluation
13:30 - 13:45
How far should we push the borderline transfemoral access for TAVR? Techniques, equipment, and likelihood of glory versus gory

Evaluated
Evaluation

Speaker: K. Spargias

13:45 - 14:00
To split or not to split? The role of BASILICA and LAMPOON as adjuvant procedures during TAVR and TMVR

Evaluated
Evaluation

Speaker: J. Velianou(   )

14:00 - 14:15
The rapid emergence of transcaval TAVR. Techniques and clinical outcomes

Evaluated
Evaluation

Speaker: M. Kasel(   )

14:15 - 14:30
TAVR in the decompensated patient with AS. How to evaluate and treat

Evaluated
Evaluation

Speaker: P. Dardas(   )

14:30 - 14:45
Live-in-a-box TAVR

Evaluated
Evaluation
14:45 - 15:00
Discussion

Chairmen: S. Konstantinidis, F. Mitropoulos, C. Olympios, K. Triantafillou

Commentators: P. Kalyvas, D. Ketikoglou, K. H. Papadopoulos

15:00 - 16:15
TAVR Session VI – Looking to the future. Innovative ideas in a rapidly-evolving domain 

Evaluated
Evaluation
15:00 - 15:10
Supra-annular TAVR devices. The real and possible advantages and disadvantages

Evaluated
Evaluation

Speaker: K. Spargias

15:10 - 15:20
The ACCURATE Neo TAVR system. Program Update, clinical data, patient selection and future vision

Evaluated
Evaluation

Speaker: A. Holzamer(   )

15:20 - 15:30
The PORTICO TAVR system. Program Update, clinical data, patient selection and future vision

Evaluated
Evaluation

Speaker: L. Michalis(   )

15:30 - 15:40
Medtronic Structural Heart Pipeline

Evaluated
Evaluation

Speaker: V. Martzaklis(   )

15:40 - 15:50
What to expect in the near future from the market leaders? The Sapien family and the CENTERA self-expandable valve. Program Update, clinical data and patient selection

Evaluated
Evaluation

Speaker: M. Kasel(   )

15:50 - 16:00
A Deep Dive Into TAVR Cost-Effectiveness Studies with constantly moving goalposts

Evaluated
Evaluation

Speaker: L. Michalis(   )

16:05 - 16:15
Discussion

Evaluated
Evaluation

Chairmen: G. Bompotis, A. Dimas, C. Kotoulas, S. Patsilinakos

Commentators: D. Damaskos, C. Moldovan, L. Poulimenos

16:15 - 16:30
BREAK 

16:30 - 17:30
JOINT SESSION  

SPECIAL LECTURES

Evaluated
Evaluation
16:30 - 16:50
TAVR device selection in the real world. Based on clinical, anatomical and device factors

Evaluated
Evaluation

Speaker: M. Kasel(   )

16:50 - 17:10
Three-Dimensional Echocardiography is key

Evaluated
Evaluation

Speaker: J. Kisslo

17:10 - 17:30
Patient selection for transcatheter tricuspid edge-to-edge grasping and clinical outcomes

Evaluated
Evaluation

Speaker: F. Maisano

Chairmen: A. Dagre, S. Pattakos

17:30 - 19:00
Mitral and Tricuspid Session II – Looking to the future 

Evaluated
Evaluation
17:30 - 17:45
Advanced echocardiography assessment of the tricuspid valve and right ventricular function and implications for transcatheter treatment

Evaluated
Evaluation

Speaker: M. Chrissoheris(   )

17:45 - 18:00
Technical tips and tricks to successful perform transseptal puncture for Mitraclip and TMVR procedures

Evaluated
Evaluation

Speaker: K. Spargias

18:00 - 18:15
An often Challenging MitraClip Decision: Whether to Implant a second (or third) Clip

Evaluated
Evaluation

Speaker: V. Ninios(   )

18:15 - 18:30
Transcatheter valve-in-valve and valve-in-ring in the tricuspid position. Patient selection, tips and tricks and outcomes

Evaluated
Evaluation

Speaker: A. Tzifa(   )

18:30 - 18:45
Minimally invasive surgery for isolated TR repair

Evaluated
Evaluation

Speaker: A. Pitsis

18:45 - 19:00
The Structural Heart and Valve Center: The Roles of Cardiovascular Team Professionals

Evaluated
Evaluation

Speaker: S. Pattakos(   )

Chairmen: N. Georgakopoulos, S. Kyrzopoulos, G. Makos, A. Patrianakos

Commentators: A. Manolis, S. Kounas, G. Moustogiannis

19:00 - 21:00
My best and/or my worst Structural Procedure of the year 

Evaluated
Evaluation
19:00 - 19:10

Evaluated
Evaluation

Speaker: C. Arampatzis(   )

19:10 - 19:20

Evaluated
Evaluation

Speaker: J. Iakovou(   )

19:20 - 19:30

Evaluated
Evaluation

Speakers: G. Katsimagklis(   ),

19:30 - 19:40

Evaluated
Evaluation

Speaker: D. Nikas

19:40 - 19:50

Evaluated
Evaluation

Speaker: V. Ninios

19:50 - 20:00

Evaluated
Evaluation

Speaker: K. Perreas(   )

20:00 - 20:10

Evaluated
Evaluation

Speaker: K. Spiliotopoulos(   )

20:10 - 20:20

Evaluated
Evaluation

Speaker: K. Triantafyllou(   )

20:20 - 20:30

Evaluated
Evaluation

Speaker: D. Tsikaderis(   )

20:30 - 20:40

Evaluated
Evaluation

Speaker: I. Zarifis(   )

Chairmen: N. Kafkas, A. Spanos, G. Triantis

Commentators: N. Koutsogiannis, M. Panagiotou, S. Papaioannou